$PL
Planet Labs PBC

2021 Q1 Form 10-Q Financial Statement

#000119312521182983 Filed on June 04, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q4
Revenue $30.28M $82.89M
YoY Change
Cost Of Revenue $22.83M $64.56M
YoY Change
Gross Profit $7.456M $18.33M
YoY Change
Gross Profit Margin 24.62% 22.11%
Selling, General & Admin $16.63M $52.77M
YoY Change
% of Gross Profit 223.08% 287.9%
Research & Development $11.38M $32.44M
YoY Change
% of Gross Profit 152.68% 176.99%
Depreciation & Amortization $15.91M $46.30M
YoY Change
% of Gross Profit 213.41% 252.61%
Operating Expenses $28.02M $85.21M
YoY Change
Operating Profit -$322.9K -$66.88M
YoY Change
Interest Expense -$16.15M -$23.35M
YoY Change
% of Operating Profit
Other Income/Expense, Net -$14.23M $520.0K
YoY Change
Pretax Income -$36.99M -$89.04M
YoY Change
Income Tax $504.0K $569.0K
% Of Pretax Income
Net Earnings -$14.55M -$89.61M
YoY Change
Net Earnings / Revenue -48.05% -108.11%
Basic Earnings Per Share
Diluted Earnings Per Share -$142.7K -$341.1K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $858.8K
YoY Change
Cash & Equivalents $71.18M $0.00
Short-Term Investments
Other Short-Term Assets $609.1K
YoY Change
Inventory
Prepaid Expenses $609.1K $0.00
Receivables $47.11M
Other Receivables
Total Short-Term Assets $125.4M $0.00
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $159.9M
YoY Change
Goodwill $88.39M
YoY Change 0.0%
Intangibles $5.673M
YoY Change
Long-Term Investments $345.1M
YoY Change
Other Assets $2.984M
YoY Change
Total Long-Term Assets $273.9M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $125.4M $0.00
Total Long-Term Assets $273.9M
Total Assets $399.3M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.446M $10.00K
YoY Change
Accrued Expenses $280.3K $51.00K
YoY Change
Deferred Revenue $57.57M
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $108.8M $62.15K
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $1.287M
YoY Change
Total Long-Term Liabilities $1.287M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $108.8M $62.15K
Total Long-Term Liabilities $1.287M
Total Liabilities $291.8M $62.15K
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$639.9M -$1.400K
YoY Change
Common Stock $4.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $107.5M $23.60K
YoY Change
Total Liabilities & Shareholders Equity $399.3M $85.75K
YoY Change

Cashflow Statement

Concept 2021 Q1 2020 Q4
OPERATING ACTIVITIES
Net Income -$14.55M -$89.61M
YoY Change
Depreciation, Depletion And Amortization $15.91M $46.30M
YoY Change
Cash From Operating Activities -$261.3K -$28.10M
YoY Change
INVESTING ACTIVITIES
Capital Expenditures -$6.272M -$23.85M
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$252.0K -$422.0K
YoY Change
Cash From Investing Activities -$345.0M -$24.28M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 346.1M 83.84M
YoY Change
NET CHANGE
Cash From Operating Activities -261.3K -28.10M
Cash From Investing Activities -345.0M -24.28M
Cash From Financing Activities 346.1M 83.84M
Net Change In Cash 858.8K 31.47M
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$261.3K -$28.10M
Capital Expenditures -$6.272M -$23.85M
Free Cash Flow $6.011M -$4.242M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
dMY Technology Group, Inc. IV
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
0
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q1 dei Entity File Number
EntityFileNumber
001-40166
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-2992192
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
1180 North Town Center Drive
CY2021Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Las Vegas
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
89144
CY2020Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
750
CY2021Q1 dei City Area Code
CityAreaCode
702
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
781-4313
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-14549315
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
23600
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-14549315
CY2021Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-495335
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Entity Shell Company
EntityShellCompany
true
CY2021Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001836833
CY2021Q1 us-gaap Cash
Cash
858767
CY2020Q4 us-gaap Cash
Cash
0
CY2021Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
609092
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
0
CY2021Q1 us-gaap Assets Current
AssetsCurrent
1467859
CY2020Q4 us-gaap Assets Current
AssetsCurrent
0
CY2021Q1 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
345051009
CY2020Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
0
CY2021Q1 us-gaap Assets
Assets
346518868
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
104527
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
10000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
280310
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
51000
CY2021Q1 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
50450
CY2020Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
400
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
435287
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
62150
CY2021Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
34679665
CY2020Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0
CY2021Q1 us-gaap Liabilities
Liabilities
47189952
CY2020Q4 us-gaap Liabilities
Liabilities
62150
CY2021Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
294328910
CY2020Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
19549351
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
24137
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-14550715
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1400
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
5000006
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
346518868
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
85750
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
272868
CY2021Q1 us-gaap Franchisor Costs
FranchisorCosts
50050
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-322918
CY2021Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
4
CY2021Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-495335
CY2021Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
184092
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
85333
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
109290
CY2021Q1 dmyq Increasedecrease In Franchise Tax Payable
IncreasedecreaseInFranchiseTaxPayable
50050
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-261333
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
858767
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
0
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
858767
CY2021Q1 dmyq Change Value Of Classa Common Stock Subject To Possible Redemption
ChangeValueOfClassaCommonStockSubjectToPossibleRedemption
294328910
CY2021Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
34500000
CY2021Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
10.00
CY2021Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
345000000
CY2021Q1 dmyq Initial Public Offering Costs
InitialPublicOfferingCosts
19600000
CY2021Q1 us-gaap Deferred Offering Costs
DeferredOfferingCosts
12100000
CY2021Q1 dmyq Business Combination Within In Combination Period Possible Per Share Value Of Residual Assets Remaining Available For Distribution
BusinessCombinationWithinInCombinationPeriodPossiblePerShareValueOfResidualAssetsRemainingAvailableForDistribution
10.00
CY2021Q1 dmyq Business Combination Required Completion Period After Initial Public Offering
BusinessCombinationRequiredCompletionPeriodAfterInitialPublicOffering
P24M
CY2021Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation limit of $250,000. As of March&#160;31, 2021 and December&#160;31, 2020, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with U.S. GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these financial statements is the determination of the fair value of the warrant liability. Accordingly, the actual results could differ significantly from those<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">estimates. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2021Q1 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2021Q1 dmyq Restricted Investments Maturity Period
RestrictedInvestmentsMaturityPeriod
P185D
CY2021Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2021Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
8900000
CY2021Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
6914050
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
346120100
CY2021Q1 dmyq Deferred Offering Costs Included In Note Payable
DeferredOfferingCostsIncludedInNotePayable
9194
CY2021Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q1 dmyq Offering Costs Included In Accrued Expenses
OfferingCostsIncludedInAccruedExpenses
170020
CY2021Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
991000
CY2021Q1 dmyq Underwriting Discount Of Per Unit
UnderwritingDiscountOfPerUnit
0.20
CY2021Q1 us-gaap Payments For Underwriting Expense
PaymentsForUnderwritingExpense
6900000
CY2021Q1 dmyq Additional Fee For Deferred Underwriting Commissions Per Unit
AdditionalFeeForDeferredUnderwritingCommissionsPerUnit
0.35
CY2021Q1 dmyq Deferred Underwriter Fee
DeferredUnderwriterFee
12100000
CY2021Q1 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Stockholders of record are entitled to one vote for each share held on all matters to be voted on by stockholders. Holders of Class A common stock and holders of Class B common stock will vote together as a single class on all matters submitted to a vote of the stockholders except as required by law.
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000
CY2021Q1 dmyq Warrants Expire Date
WarrantsExpireDate
upon a minimum of 30 days&#8217; prior written notice of redemption
CY2021Q1 dmyq Warrant Redemption Price Description
WarrantRedemptionPriceDescription
at a price of $0.01 per warrant
CY2021Q1 dmyq Class Of Warrant Or Right Exercisable Description
ClassOfWarrantOrRightExercisableDescription
on the later of (a) 30 days after the completion of a Business Combination or (b) 12 months from the closing of the Initial Public Offering
CY2021Q1 dmyq Offering Costs Paid By Related Party Under Promissory Note
OfferingCostsPaidByRelatedPartyUnderPromissoryNote
439100
CY2021Q1 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
990856
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NV
CY2021Q1 us-gaap Deferred Costs
DeferredCosts
0
CY2020Q4 us-gaap Deferred Costs
DeferredCosts
85750
CY2021Q1 dmyq Deferred Underwriting Commissions
DeferredUnderwritingCommissions
12075000
CY2020Q4 dmyq Deferred Underwriting Commissions
DeferredUnderwritingCommissions
0
CY2021Q1 dmyq Offering Costs Associated With Derivative Warrant Liabilities
OfferingCostsAssociatedWithDerivativeWarrantLiabilities
710745
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-14226397
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
332787000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
18932369
CY2021Q1 dmyq General And Administrative Expenses Paid In Kind
GeneralAndAdministrativeExpensesPaidInKind
1000
CY2021Q1 dmyq Offering Costs Associated With Derivative Warrant Liabilities
OfferingCostsAssociatedWithDerivativeWarrantLiabilities
710745
CY2021Q1 us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
345000000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-345000000
CY2021Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
125006
CY2021Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
345000000
CY2021Q1 dmyq Prepaid Expenses Paid By Related Party Under Promissory Note
PrepaidExpensesPaidByRelatedPartyUnderPromissoryNote
425000
CY2021Q1 dmyq Reversal Of Accrued Expenses
ReversalOfAccruedExpenses
50000
CY2021Q1 dmyq Deferred Underwriting Commissions In Connection With The Initial Public Offering
DeferredUnderwritingCommissionsInConnectionWithTheInitialPublicOffering
12075000
CY2021Q1 dmyq Fair Value Transfer Between Levels
FairValueTransferBetweenLevels
0
CY2021Q1 us-gaap Stock Redeemed Or Called During Period Value
StockRedeemedOrCalledDuringPeriodValue
-294328910
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q1 dmyq Increase Decrease To Derivative Warrant Liabilities
IncreaseDecreaseToDerivativeWarrantLiabilities
21100000
CY2021Q1 dmyq Adjustment For Gain Loss On Investment Dividend Interest Held In Trust Account
AdjustmentForGainLossOnInvestmentDividendInterestHeldInTrustAccount
-51009
CY2021Q1 dmyq Gain Loss On Investment Dividend Interest Held In Trust Account
GainLossOnInvestmentDividendInterestHeldInTrustAccount
51009
CY2021Q1 dmyq Gain Loss Upon Issuance Of Private Placemen Twarrants
GainLossUponIssuanceOfPrivatePlacemenTwarrants
-14062000
CY2021Q1 dmyq Gain Loss Upon Issuance Of Private Placemen Twarrants
GainLossUponIssuanceOfPrivatePlacemenTwarrants
-14062000

Files In Submission

Name View Source Status
0001193125-21-182983-index-headers.html Edgar Link pending
0001193125-21-182983-index.html Edgar Link pending
0001193125-21-182983.txt Edgar Link pending
0001193125-21-182983-xbrl.zip Edgar Link pending
d170734d10q.htm Edgar Link pending
d170734dex311.htm Edgar Link pending
d170734dex312.htm Edgar Link pending
d170734dex321.htm Edgar Link pending
d170734dex322.htm Edgar Link pending
dmyq-20210331.xml Edgar Link completed
dmyq-20210331.xsd Edgar Link pending
dmyq-20210331_cal.xml Edgar Link unprocessable
dmyq-20210331_def.xml Edgar Link unprocessable
dmyq-20210331_lab.xml Edgar Link unprocessable
dmyq-20210331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending